Company has received an In-principle approval for the proposed partly paid-up Rights Issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech Ltd has received an in-principle approval from BSE (dated 19 September 2025) for its proposed Rights Issue of partly paid-up equity shares. The company had applied for this approval on 12 April 2025, and the BSE has now permitted the company to use the exchange's name in its Letter of Offer, subject to standard disclaimers and compliance requirements. Key details such as the issue size, rights issue price, entitlement ratio, and record date have not been disclosed yet — these are expected to be announced at least 3 working days before the record date. The company will need to complete further statutory and listing formalities before finalising the offer documents and proceeding with the issue.
This is a routine procedural milestone that moves the company one step closer to launching a capital raise from existing shareholders. For investors, it signals that a rights issue is coming, which may involve dilution if not fully subscribed, but actual impact on share price will depend on the issue price, ratio, and timing — none of which have been disclosed yet.